Men born with a high risk of developing prostate cancer should have additional screening every year from the age of 40, experts say.
Men are certainly mutations in their DNA, their genetic code is more likely to develop prostate cancer.
Researchers at the Cancer Research Institute (ICR) say that an annual blood test can help detect tumors earlier when they are easy to treat.
Prostate cancer UK says that all decisions must be made carefully.
ICR researchers said that about one in 300 men in the UK had mutations in Brca2, which increased their risk.
However, most will not know whether they carry the mutation in their DNA since they have not been routinely tested.
Mutations in Brca2 are the same genetic errors that increase the risk of breast and ovarian cancer in women ̵
Prostate-specific antigen (PSA) is a protein produced only by the prostate gland.
PSA levels increase with prostate cancer, but this is not a reliable enough measure to justify the screening of all men for the disease,
Prof. Ross Ails says: "Our study shows very clearly that men with the Brca2 gene are at increased risk for aggressive prostate cancer and that regular PSA testing may go some way to improving early diagnosis and treatment.
She said that men with mutations in Brca2 were almost twice as likely to have severe cancer that needed treatment rather than simple observation.
Dr Matthew Hobbs, of the UK prostate cancer charity, stated: "[We are] financing a project to model the long-term effectiveness of a number of potential screening strategies, including determining whether there are certain high-risk groups for whom the benefits of regular screening far outweigh the potential for overtraining.
"Screening of all men with a Brca2 mutation may be one of the answers, so we will look carefully at the results of this study."